Skip to main content

Table 2 Usual practice when seeing patients with cognitive symptoms of mild severity

From: Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

 

Never

Rarely

Sometimes

Routinely

p value*

Patient counseling

 - Diet and nutrition

EAN/EADC

9 (8.8)

11 (10.8)

32 (31.4)

49 (48)

0.17

AAN

57 (13.6)

69 (16.4)

132 (31.5)

162 (38.5)

 

 - Vitamins

EAN/EADC

16 (15.7)

24 (23.5)

38 (37.3)

23 (22.5)

0.29

AAN

49 (11.6)

84 (20.1)

155 (36.9)

132 (31.4)

 

 - Mental exercise

EAN/EADC

1 (1)

4 (3.9)

13 (12.7)

83 (81.4)

0.41

AAN

13 (3.0)

21 (5.1)

71 (17.0)

315 (74.9)

 

 - Physical exercise

EAN/EADC

3 (2.9)

4 (3.9)

13 (12.7)

82 (80.4)

0.78

AAN

8 (1.8)

19 (4.5)

67 (15.9)

327 (77.8)

 

 - Alcohol

EAN/EADC

18 (17.6)

14 (13.7)

32 (31.4)

36 (35.3)

**

Patient education

 - Advance planning

EAN/EADC

1 (1)

21 (20.6)

42 (41.2)

37 (36.3)

0.08

AAN

33 (7.9)

84 (20.0)

172 (41.0)

130 (31)

 

 - Driving

EAN/EADC

3 (2.9)

16 (15.7)

42 (41.2)

41 (40.2)

0.82

AAN

11 (2.6)

52 (12.3)

186 (44.2)

172 (40.9)

 

 - Research studies

EAN/EADC

2 (2)

12 (11.8)

47 (46.1)

40 (39.2)

< 0.0001*

AAN

27 (6.4)

109 (26)

199 (47.4)

85 (20.2)

 

 - Support services

EAN/EADC

0

17 (16.7)

37 (36.3)

46 (45.1)

0.001*

AAN

18 (4.3)

92 (21.9)

195 (46.4)

115 (27.3)

 

 - Recommendations for follow-up

EAN/EADC

0

1(1)

8 (7.8)

91 (89.2)

0.75

AAN

0

5 (1.3)

44 (10.4)

371 (88.3)

 

 - Risk of AD and related disorder (general terms)

EAN/EADC

1 (1)

5 (4.9)

25 (24.5)

70 (68.6)

0.55

AAN

4 (1)

37 (8.9)

113 (27)

265 (63)

 

 - Risk of AD and related disorders (numeric estimates)

EAN/EADC

7 (6.9)

24 (23.5)

47 (46.1)

22 (21.6)

0.17

AAN

47 (11.1)

125 (29.8)

150 (35.7)

98 (23.4)

 

 - Referral to Alzheimer’s association or similar association

EAN/EADC

15 (14.7)

34 (33.3)

35 (34.3)

16 (15.7)

0.22

AAN

82 (19.5)

153 (36.5)

146 (34.7)

39 (9.3)

 

 - Written summary letter of findings for patient

EAN/EADC

9 (8.8)

13 (12.7)

25 (24.5)

54 (52.9)

< 0.0001*

AAN

117 (27.8)

158 (37.6)

82 (19.6)

63 (14.9)

 

Medication prescribed

 - Cholinesterase inhibitors

EAN/EADC

28 (27.5)

16 (15.7)

35 (4.3)

21 (20.6)

0.01*

AAN

60 (14.3)

67 (15.9)

189 (45)

104 (24.8)

 

 - Memantine

EAN/EADC

64 (62.7)

14 (13.7)

7 (6.9)

13 (12.7)

0.0001*

AAN

147 (35.1)

108 (25.6)

129 (30.7)

36 (8.5)

 

 - Other

EAN/EADC

26 (25.5)

7 (6.9)

28 (27.5)

9 (8.8)

0.89

AAN

140 (33.3)

45 (10.8)

169 (40.2)

66 (15.7)

 
  1. All data are N (%)
  2. Abbreviations: EAN European Academy of Neurology, EADC European Alzheimer’s Disease Consortium, AAN American Academy of Neurology
  3. *Differences in replies between EAN/EADC and AAN members (chi-square)
  4. **Question not in the AAN survey